|Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.|
|Jump to Full Text|
|PMID: 20717114 Owner: NLM Status: MEDLINE|
|BACKGROUND: Cyclooxygenase-2 (COX-2) overexpression is strongly associated with colorectal tumourigenesis. It has been demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients from colorectal cancer (CRC) development and progression but induces severe cardiovascular side effects. New strategies for selective COX-2 blockade are required.
METHODS: We developed an improved technique, based on RNA interference (RNAi), to gain a selective COX-2 silencing in CRC cells by a tumour-dependent expression of anti-COX-2 short-hairpin RNA (shCOX-2). Anti-COX-2 shRNA-expressing vectors were delivered in CRC cells (in vitro) and in colon tissues (ex vivo) using engineered Escherichia coli strains, capable of invading tumour cells (InvColi).
RESULTS: A highly tumour-dependent shCOX-2 expression and a significant COX-2 silencing were observed in CRC cells following InvColi strain infection. Cyclooxygenase-2 silencing was associated with a strong reduction in both proliferative and invasive behaviour of tumour cells. We also demonstrated a pivotal role of COX-2 overexpression for the survival of CRC cells after bacterial infection. Moreover, COX-2 silencing was achieved ex vivo by infecting colon tissue samples with InvColi strains, leading to anti-inflammatory and anti-tumour effects.
CONCLUSION: Our RNAi/InvColi-mediated approach offers a promising tool for a highly selective COX-2 blockade in vitro and in vivo.
|A Strillacci; C Griffoni; G Lazzarini; M C Valerii; S Di Molfetta; F Rizzello; M Campieri; M P Moyer; V Tomasi; E Spisni|
Related Documents :
|427874 - Labelling index of human squamous cell carcinomas. comparison of in vivo and in vitro l...
17587804 - A human three-dimensional cell line model allows the study of dynamic and reversible ep...
2420694 - The prevalence, prognostic significance and hormonal content of endocrine cells in gast...
9039224 - Immunohistochemical evaluation of transglutaminase c in tumours of salivary glands.
6688084 - Selective enrichment of human epidermal cell subpopulations using monoclonal antibodies.
7394994 - Microscopic gonadoblastoma in dysgenetic gonad of an infant: an ultrastructural study.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-17|
|Title: British journal of cancer Volume: 103 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2010 Sep|
|Created Date: 2010-09-29 Completed Date: 2010-10-25 Revised Date: 2013-05-28|
Medline Journal Info:
|Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England|
|Languages: eng Pagination: 975-86 Citation Subset: IM|
|Department of Experimental Biology, University of Bologna, via Selmi 3, Bologna 40126, Italy. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Cell Line, Tumor
Colonic Neoplasms / enzymology, genetics*
Cyclooxygenase 2 / genetics*
Dinoprostone / biosynthesis
Escherichia coli / genetics*
|363-24-6/Dinoprostone; EC 220.127.116.11/Cyclooxygenase 2|
Journal ID (nlm-ta): Br J Cancer
Publisher: Nature Publishing Group
Copyright © 2010 Cancer Research UK
Received Day: 16 Month: 04 Year: 2010
Revision Received Day: 21 Month: 07 Year: 2010
Accepted Day: 22 Month: 07 Year: 2010
Print publication date: Day: 28 Month: 09 Year: 2010
Electronic publication date: Day: 17 Month: 08 Year: 2010
Volume: 103 Issue: 7
First Page: 975 Last Page: 986
Publisher Item Identifier: 6605859
PubMed Id: 20717114
|Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells Alternate Title:RNAi and COX-2 silencing in CRC cells|
|M C Valerii12|
|S Di Molfetta1|
|M P Moyer3|
1Department of Experimental Biology, University of Bologna, via Selmi 3, Bologna 40126, Italy
2Department of Clinical Medicine, St Orsola-Malpighi Hospital, via Massarenti 9, Bologna 40138, Italy
3INCELL Corporation, Cimarron Path 12734, San Antonio, TX 78249, USA
Colorectal cancer (CRC) represents the third most common tumour in humans and the second leading cause of tumour-related death in Western countries. In Europe, >4 00 000 new cases and >2 00 000 deaths per year are estimated (Ferlay et al, 2007). The mortality rate of CRC dramatically increases when tumour cells invade the primary tissue and generate lymph nodal and liver metastases. Owing to its high incidence and mortality rate, CRC is of great interest for the scientific community.
Over the last few decades, it has been demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), blocking isoforms 1 and 2 of the cyclooxygenase (COX) enzyme, confers a 40–50% reduction in the incidence of CRC (Phillips et al, 2002; Thun et al, 2002; Higuchi et al, 2003; Sandler et al, 2003). Cyclooxygenase is a key enzyme in the metabolism of arachidonate and regulates the synthesis of prostaglandins (H2, D2, E2, F2α, I2) and tromboxanes (TXA2 and TXB2), both having important roles as cellular mediators. Cyclooxygenase-2 represents the product of the Cox-2 inducible gene. It is overexpressed in 40% of adenomas and in 80% of adenocarcinomas (Eberhart et al, 1994; Sano et al, 1995), and such an overexpression has been strongly associated with colon tumourigenesis both in vitro and in murine models (DuBois et al, 1996; Oshima et al, 1996; Williams et al, 1996). It is commonly accepted that COX-2 can contribute to CRC development and progression through mechanisms involving the stimulation of angiogenesis (Spisni and Tomasi, 1997; Iñiguez et al, 2003), the inhibition of apoptosis (Tsujii and DuBois, 1995) and the increase in cell migration/invasiveness (Yamauchi et al, 2002; Strillacci et al, 2006).
Celecoxib and rofecoxib were the first NSAIDs marketed as selective COX-2 inhibitors and they have been used in clinical trials to test their efficacy in the prevention and/or treatment of CRC. Unfortunately, celecoxib and, particularly, rofecoxib have been shown to significantly increase the risk of adverse cardiovascular events and myocardial infarction in treated patients (Bresalier et al, 2005; Solomon et al, 2005). Moreover, the cardiovascular toxicity of rofecoxib could be increased by its capability to directly inhibit prostacyclin synthase activity, as demonstrated by our group (Griffoni et al, 2007). Although celecoxib is still marketed, rofecoxib has been withdrawn from the worldwide market by Merck in September 2004.
RNA interference (RNAi) has rapidly become an innovative and elective tool for gene silencing at the post-transcriptional level. RNAi-mediated gene silencing can be achieved using small interfering RNA (siRNA) or short-hairpin RNA (shRNA) as precursor molecules. Although synthetic siRNAs are introduced in mammal cells using standard in vitro transfection methods, shRNAs are expressed after transfecting cells with plasmids (Lewis et al, 2002) or viral-based vectors (Brummelkamp et al, 2002). Numerous advantages come from shRNA-based RNAi approach: first, the possibility to obtain a long-term gene silencing; and second, the possibility to express shRNAs in a spatial- and/or temporal-specific manner using tissue-specific promoters or introducing regulatory elements on shRNA promoters.
In 2006, our research group demonstrated that it is possible to stably silence the COX-2 protein in a CRC cell line (HT-29) using the anti-COX-2 shRNA (shCOX-2). HT-29pS(shCOX−2) showed a significant impairment of malignant behaviour (Strillacci et al, 2006) and a reduced ability to survive under hypoxic conditions (Sansone et al, 2009). To date, RNAi approaches have been used to efficiently silence the COX-2 protein in many different in vitro models (for a review, see Strillacci et al, 2010).
Several years ago, it was demonstrated that a functional gene transfer from bacteria to mammalian cells could occur. In particular, engineered Escherichia coli, expressing Inv and HlyA genes (from Yersinia pseudotuberculosis and Lysteria monocytogenes, respectively), was found to be able to invade and release DNA into host cells (Grillot-Courvalin et al, 1998). This phenomenon was also demonstrated in vivo, as it was observed that invasive E. coli can deliver therapeutic genes to the colonic mucosa in mice (Castagliuolo et al, 2005). Similarly, a successful transfer of shRNA into mammalian cells was achieved using non-pathogenic E. coli transformed with a plasmid containing expression cassettes for shRNA and Inv/HlyA genes. In 2006, Xiang et al (2006) applied this new strategy for the first time (termed ‘trans-kingdom RNAi') to silence the β-1 catenin gene (CTNNB1) in human cells both in vitro and in vivo.
In this paper, we describe an effective method by which shCOX-2-expressing vectors can be delivered into CRC cells (in vitro) and in COX-2-overexpressing colonic tissues (ex vivo), using invasive E. coli strains to achieve a strong COX-2 silencing mediated by RNAi, coupled to anti-tumour effects. This strategy may prove to be suitable for an in vivo application aiming at COX-2 inhibition and CRC prevention.
Human cancer cell lines HCA-7, HT-29, HCT-116, HeLa and human transformed kidney cell line HEK-293 were obtained from the American Type Culture Collection (Manassas, VA, USA). Normal human colon mucosal epithelial cell line NCM-460 (Moyer et al, 1996) was obtained after a licensing agreement with INCELL Corporation (San Antonio, TX, USA). Both HT-29pS(−) and HT-29pS(shCOX−2) cells have been previously created by our group, as described elsewhere (Strillacci et al, 2006). Cell lines were cultured at 37°C in 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 m-glutamine and kanamycin 100 μg ml−1. Both FCS and DMEM were purchased from Cambrex BioWhittaker (Charles City, IA, USA). The NCM-460 cells were cultured in the M3 base media obtained from INCELL Corporation. All other reagents were purchased from Sigma (St Louis, MO, USA).
Fresh colon biopsies were collected from patients affected by acute ulcerative colitis during endoscopy and immediately cultured in the MegaCell RPMI-1640 medium (Sigma). Patients gave written informed consent to participate in the study, which was approved by the local ethical committee.
The empty pSUPER.retro vector (pS−), based on the murine stem cell virus (MSCV) genome, was purchased from Oligoengine (Seattle, WA, USA). The pSUPER.retro vector expressing shCOX-2 under RNA pol III H1 promoter control (pSH1) was created as described elsewhere (Strillacci et al, 2006). pSUPER.retro vectors expressing shCOX-2 under control of human Cox-2 promoter (pSCOX−2) and TBE (Tcf-binding element)-based promoter (pSTBE) were created as follows: in both vectors, RNA pol III transcription stop signal was substituted with a SV40 polyA sequence between HindIII and SalI restriction sites (SV40 polyA sequence was amplified from the hER/pSG5 expression plasmid; forward primer: 5′-CCCAAGCTTAAATAAAGCAATAGCATCAC-3′ reverse primer: 5′-TAGAGTCGACCAGACATGATAAGAT-3′, 120 bp product); in pSCOX−2, the H1 promoter (pH1) was substituted with the human Cox-2 promoter sequence (pCOX-2) between ApaI and BglII restriction sites (pCOX-2 sequence was amplified from HCA-7 genomic DNA; forward primer: 5′-CGGGCCCTGAGCACTACCCATGATA-3′ reverse primer: 5′-GAAGATCTCCGAGAGAACCTTCC-3′, 1254 bp product); in pSTBE, pH1 was substituted with the TBE-based promoter sequence (pTBE) between ApaI and BglII restriction sites (the pTBE sequence was amplified from TOPFLASH plasmid, kindly provided by Dr Hans Clevers, University Hospital, Utrecht, The Netherlands; forward primer: 5′-CGGGCCCAAGCTATCAAAGGG-3′ reverse primer: 5′-CGAGATCTGGCGCCTCAGCTGGC-3′, 151 bp product). A comprehensive scheme of pS vectors described above is shown in Figure 1.
HCA-7, HT-29, HCT-116, NCM-460, HeLa and HEK-293 cells were seeded in 6-well plates (∼7 × 105 cells per well) at 70% confluence. After 24 h, cells were transfected with pS−, pSH1, pSCOX−2 and pSTBE vectors using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After 6 h of incubation at 37°C, the transfection medium was replaced with 2 ml of complete medium containing 10% FCS. Cells were lysed 48 h after transfection for real-time PCR and western blot analyses.
Total RNA from cultured cells was extracted using Eurozol reagent (Celbio, Milan, Italy) according to the manufacturer's instructions. Extracted RNA samples were treated with DNase I to remove any genomic DNA contamination using DNA-free kit (Ambion, Austin, TX, USA) and reverse transcribed using RevertAid First-Strand cDNA Synthesis Kit (Fermentas, Burlington, Ontario, Canada). Both COX-2 and β-glucuronidase (GUSB) mRNAs were reverse transcribed using random hexamer primers (Fermentas). The siCOX-2 was reverse transcribed using the stem-loop RT–PCR technique (Chen et al, 2005) using the following primer: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAATTCC-3′. U6 RNA was reverse transcribed using the following primer: 5′-AAAATATGGAACGCTTCACG-3′. Both COX-2 mRNA and siCOX-2 levels were analysed by real-time PCR using SYBR supermix (Bio-Rad, Hercules, CA, USA) and iCycler system (Bio-Rad) according to the manufacturer's instructions. The melting curve data were collected to check PCR specificity. Each cDNA sample was analysed in triplicate. Cyclooxygenase-2 mRNA levels were normalised against GUSB mRNA, whereas siCOX-2 expression was normalised against U6 RNA levels. Relative expressions were calculated using the formula 2−2ΔCt values (ΔCt=Ctgene−Cthk). Cyclooxygenase-2 primer pair: 5′-CCTGTGCCTGATGATTGC-3′ and 5′-CTGATGCGTGAAGTGCTG-3′ (165 bp product); siCOX-2 primer pair: 5′-GCAACTGCTCAACACCG-3′ and 5′-TGCAGGGTCCGAGGTAT-3′ (56 bp product); GUSB primer pair: 5′-TGGTATAAGAAGTATCAGAAGCC-3′ and 5′-GTATCTCTCTCGCAAAAGGAAC-3′ (297 bp product); U6 primer pair: 5′-CTTCGGCAGCACATATACT-3′ and 5′-AAAATATGGAACGCTTCACG-3′ (99 bp product).
The E. coli (DH5α strain) was co-transformed with the pGB2-Ω-inv-hly plasmid (SmR+, kindly provided by Dr Catherine Grillot-Courvalin, Institut Pasteur, Paris) and pSUPER.retro (AmpR+) vectors to obtain E. coli invasive strains carrying the three different shCOX-2 expression vectors (namely InvColi-pSH1, InvColi-pSCOX−2 and InvColi-pSTBE) and the negative control (InvColi-pS−). Selection of co-transformed strains was based on both streptomycin and ampicillin resistance. Both HT-29 and HCA-7 cell lines were infected with InvColi strains according to the following procedure: cells were seeded in 25 cm2 flasks at 50% confluence (∼3 × 106 cells) in an antibiotic-free medium (DMEM); InvColi strains were grown in LB medium at 37°C to reach an OD600 of ∼1.00; InvColi bacteria were then washed twice in fresh LB medium, re-suspended in antibiotic-free DMEM and added to cells' media at an MOI (multiplicity of infection) of 1:1000; after 2 h of incubation at 37°C in 5% CO2, cells were washed and fresh DMEM medium supplemented with kanamycin was added to the flasks. Cells were lysed 48 h after infection for western blot and real-time PCR analyses. With regard to colon tissue samples, infection was achieved immediately after endoscopic resection by co-culturing biopsies and InvColi-pS strains in MegaCell RPMI-1640 medium as described above. Biopsies were lysed and supernatants were collected 48 h after infection for western blot, real-time PCR and Luminex (Luminex, Austin, TX, USA) analyses.
Cultured cells were homogenised in lysis buffer (50 m Tris-HCl, pH 7.5, 2 m EDTA, 100 m NaCl, 1% Triton X-100, protease inhibitors mixture). Cell lysates were incubated 1 h on ice and centrifuged at 12 000 g to collect supernatants. After addition of SDS–PAGE sample buffer and boiling, 40 μg of denatured proteins was separated in 12% SDS–PAGE and then transferred onto nitrocellulose papers. After blotting, nitrocellulose papers were incubated with specific antibodies. The primary antibodies used were polyclonal anti-COX-2 (Cayman Chemicals, Ann Arbor, MI, USA) and anti-β-actin (Sigma). Secondary antibodies (HRP conjugated) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunolabelling was visualised using the ECL procedure (Amersham Biosciences, Piscataway, NJ, USA). Bands were quantified using densitometric image analysis software (Quantity One, Bio-Rad). Normalisation was made against β-actin expression.
InvColi pSTBE-infected cells were analysed 48 h after infection using the Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan) to detect green fluorescent protein (GFP) expression. The total DNA of infected cells was extracted using phenol/chloroform procedure 24 h after infection, and the presence of pGB2-Ω-inv-hly and pSTBE plasmids was confirmed by standard PCR technique, followed by agarose gel electrophoresis analysis. Inv primer pair: 5′-GCCAATAAGGAGCAGGAGAC-3′ and 5′-CCAAGGAGCCAGCCAATC-3′ (225 bp product); HlyA primer pair: 5′-CATTTCACATCGTCCATCTATTTG-3′ and 5′-TACCGTTCTCCACCATTCC-3′ (100 bp product); pTBE sequence primer pair (see above). The PCR analysis was also performed on E. coli co-transformed with pGB2-Ω-inv-hly and pSTBE plasmids (pre-heated at 95°C for 5 min) and on purified plasmids themselves.
Both HT-29 and HCA-7 cells were infected with InvColi strains. Twenty-four hours after infection (day 0), cells were seeded in 12-well plates (HT-29: 5 × 104 cells per well; HCA-7: 2 × 104 cells per well). On days 1, 2, 3, 6 and 8, cells were trypsinised, re-suspended in PBS 1 × and incubated for 10 min in 0.4% Trypan Blue (Sigma). Cells were then counted in a haemocytometer for unstained (viable) and stained cells. The percentage of cell viability was calculated as ((number of unstained cells)/(number of total cells)) × 100.
Invasion assay was performed using Boyden chambers (New Technologies Group, Milan, Italy) with 8-μm pore polycarbonate membranes (New Technologies Group). Membranes were coated with Matrigel (Sigma) at 40-fold dilution. Assay was performed using fresh DMEM supplemented with 10% heat-inactivated FCS as the chemoattractant agent. Forty-eight hours after InvColi infection, viable HT-29 and HCA-7 cells were added into the upper chamber at high density (3 × 105 cells) either in the absence or presence of phorbol 12-myristate 13-acetate (PMA) 40 n stimulation and then incubated for 24 h at 37°C. After incubation, membranes were disassembled and non-invasive cells on the upper surface of the membrane were wiped with a cotton swab. The invasion index was determined by counting under light microscopy the number per optical fields ( × 200 magnification) of cells that migrated to the lower side of each membrane, after fixing and staining membranes with 2% Toluidine Blue.
Simultaneous detection of 29 extracellular factors released by treated colon tissue samples was performed using Luminex technology based on multiplexed bead immunoassay. Before assay, cell media samples were concentrated 10 times using Microcon spin devices (YM3, Millipore, Billerica, MA, USA) and subsequently re-suspended in Bio-Plex (Bio-Rad) assay buffer. The levels of 27 cytokines, chemokines and growth factors (IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, PDGF-bb, bFGF, G-CSF, GM-CSF, VEGF, TNFα, IFNγ, IP-10, Eotaxin, MCP-1, MIP-1α, MIP-1β, Rantes) were measured using the human ultrasensitive cytokine 27-plex antibody bead kit (Bio-Rad). The IL-1α level was measured using Milliplex Map kit (Millipore), whereas PGE2 levels were measured using the Luminex Prostaglandin E2 Kit (Cayman Chemicals). The assays were performed in 96-well filter plates, as per the manufacturers' instructions. Concentration values were estimated using a standard curve and a fifth-order polynomial equation and were expressed as ng ml−1 or log (pg ml−1), after adjusting for the dilution factor (Bio-Plex Manager software 5.0, Bio-Plex). The intra-assay CV, including ultrafiltration and immunoassay, averaged 20%.
Data were expressed as mean±s.e.m. of three independent experiments. Analysis of variance was used to assess the statistical significance of the differences. Differences were considered statistically significant at P<0.01.
In 2006, our group demonstrated that the COX-2 protein can be efficiently and stably downregulated by a constitutive expression of siRNA targeting COX-2 mRNA (siCOX-2) (Strillacci et al, 2006). The HT-29 colon cancer cell line was transduced with a retroviral vector (pSUPER.retro) containing an expressing cassette for shCOX-2 (siCOX-2 precursor molecule). In the pSUPER.retro vector, the transcription of shRNA sequence is driven by the human H1 promoter for RNA pol III (pSH1). H1-driven transcription leads to a constitutive expression of shRNA molecules in almost every different type of transduced human cells. To improve the selectivity of siCOX-2 expression, we modified the expression cassette of shCOX-2 by substituting the promoter element. In particular, we created the pSCOX−2 vector, in which the H1 promoter (pH1) was substituted with the human Cox-2 promoter (pCOX-2), and the pSTBE vector, in which pH1 was substituted with a promoter containing TBEs (pTBEs), derived from TOPFLASH plasmid (largely used for luciferase assays). In both cases, shCOX-2 transcription is driven by RNA pol II that needs a polyA stop signal (which has been introduced in pS-modified vectors, downstream of shCOX-2 sequence) (Figure 1). Using this approach, we made shCOX-2 expression dependent on COX-2 and on Wnt/β-catenin cellular pathways, both highly activated in CRC cells. In fact, it is well known that CRC cells overexpress the COX-2 protein and this phenomenon depends on transcriptional (Yamamoto et al, 1995; Duque et al, 2005; Wu et al, 2005; Kaidi et al, 2006) and post-transcriptional regulation (Dixon et al, 2001; Strillacci et al, 2009). On the other hand, β-catenin is preferentially localised at the plasma membrane of normal colonocytes and promotes cellular adhesion, linking E-cadherin to the cytoskeleton. In CRC cells, as a consequence of mutations (Morin et al, 1997) and/or other cellular stimuli (Brabletz et al, 2001; Castellone et al, 2005), β-catenin frequently translocates in the nucleus and promotes the transcription of genes involved in cell proliferation, migration, survival, angiogenesis and stemness (Brabletz et al, 2005). In the nucleus, β-catenin associates with the transcriptional complex Tcf-4/Lef-1 (T-cell factor 4/lymphoid enhancer factor 1) and binds DNA on TBE promoter sequences. Figure 2 shows the expression levels of siCOX-2 in different human cell lines transiently transfected with pS− (empty vector, negative control), pSH1, pSCOX−2 and pSTBE vectors. By transfecting CRC cell lines with pSCOX−2 and pSTBE vectors, it is possible to gain a highly selective expression of siCOX-2. In fact, in HT-29 and HCA-7 colon cancer cells, siCOX-2 expression driven by pCOX-2 and pTBE promoters resulted to be even higher than siCOX-2 expression driven by the pH1 promoter. As expected, in the HCT-116 colon cancer cell line (that does not express the COX-2 protein), we did not record a significant expression of siCOX-2 driven by pCOX-2, whereas siCOX-2 expression driven by pTBE was slightly higher than pH1. On the contrary, in NCM-460 (normal epithelial colon cells), HeLa (human cervix carcinoma cells) and HEK-293 (human transformed kidney cell line) cells, siCOX-2 expression driven by pCOX-2 and pTBE resulted to be very low, if compared with pH1-driven siCOX-2 expression.
In 1998, Grillot-Courvalin et al (1998) showed that an engineered E. coli strain, expressing heterologous Inv and HlyA genes, was able to infect/invade mammalian cells and release DNA into host cells. On the basis of this approach, we developed a strategy to induce an RNAi-mediated COX-2 silencing in HT-29 and HCA-7 colon cancer cell lines. Bacterial LPS is known to induce COX-2 expression in human cells (Hla and Neilson, 1992). Thus, we first tested bacterial infection on CRC cells using InvColi-pS− (see the ‘Materials and Methods' section for details on InvColi-pS strains) at different MOIs. At an MOI value of 1:1000, we did not record any significant COX-2 overexpression due to the presence of bacterial LPS (data not shown). Second, we provided evidence that InvColi strains created in our laboratory were able to infect and invade human CRC cells at an MOI of 1:1000. To this purpose, we used the InvColi-pSTBE. pSTBE vector, as the other pS vectors described above, carries a GFP reporter gene. Both HT-29 and HCA-7 cells infected with InvColi-pSTBE started to express the GFP protein 48 h after infection (Figure 3A and B). An ∼90% infection/invasion efficiency was estimated on both cell lines. Moreover, soon after infection, it was possible to detect inside the cells, by PCR analysis, the presence of Inv-HlyA and pTBE sequences, carried by the pGB2-Ω-inv-hly plasmid and pSTBE vector, respectively (Figure 3C).
Using the InvColi-mediated RNAi approach, we achieved a high COX-2 silencing in CRC cell lines. In fact, 48 h after infection with invasive InvColi strains transformed with shCOX-2-expressing vectors (InvColi-pSH1, InvColi-pSCOX−2 and InvColi-pSTBE), we started to observe a significant reduction in COX-2 protein and mRNA levels in HT-29 and HCA-7 cells (Figure 3D and E). Interestingly, COX-2 silencing with InvColi-pSTBE was more effective than the silencing obtained with InvColi-pS− (negative control) or InvColi-pSH1/COX−2 bacteria. Most likely, the stronger COX-2 silencing obtained with InvColi-pSTBE was dependent on a higher siCOX-2 expression, as detected in both HT-29 and HCA-7 cells (Figure 3D and E). Silencing results were highly comparable with those obtained after transfection of pS vectors into HT-29 and HCA-7 cells using the Lipofectamine 2000 Transfection Reagent (Invitrogen) (see Supplementary Material). We recorded a significant COX-2 protein silencing up to 5 days after InvColi-pS infection (data not shown). Very interestingly, prolonged COX-2 inhibition was associated with a strong impairment of PGE2 production (Figure 4) and, as previously demonstrated with western blot analysis, the strongest inhibitory effect was obtained after InvColi-pSTBE infection.
We also evaluated whether COX-2 silencing induced by InvColi-RNAi might have been the result of an off-target effect depending on interferon system activation (in particular, the Jak-STAT pathway) (Sledz et al, 2003). Western blot analysis of phospho-STAT-1(Tyr701) (active form) levels, normalised against p85/p91 STAT-1 total protein levels, showed that the interferon system response was triggered only at high MOI values (1:100), whereas infection at MOI 1:1000 did not have any effect on STAT-1 phosphorylation (data not shown).
As we have demonstrated an effective COX-2 silencing in CRC cells mediated by InvColi-pS strains, we have further investigated the phenotype of infected cells. Figure 5 shows data regarding proliferation and viability of COX-2-silenced HT-29 (Figure 5A and B) and HCA-7 (Figure 5C and D) cells and results were in high accordance in both cell lines. InvColi-pSCOX−2 and, in particular, InvColi-pSTBE infection induced a significant reduction in CRC cell proliferation and viability, despite InvColi-pSH1 infection that led only to a slight reduction. As COX-2 overexpression is involved in the malignant behaviour and invasiveness of CRC cells, we analysed the effect of the specific COX-2 silencing mediated by InvColi-RNAi in HT-29 and HCA-7 cells by performing a cell invasion assay, 48 h after InvColi infection. The invasion index of both cell lines was significantly reduced after COX-2 silencing (Figure 6A and B). Although in HT-29 we did not record any significant difference between the effectiveness of InvColi-pSH1, InvColi-pSCOX−2 and InvColi-pSTBE, in HCA-7 InvColi-pSCOX−2 and InvColi-pSTBE, infection induced a stronger reduction in the invasion index with respect to InvColi-pSH1. The impairment of the invasive behaviour of CRC cells due to RNAi-mediated COX-2 silencing was further confirmed after stimulation with PMA, which is known to induce COX-2 expression (Crofford et al, 1994) and promote cancer cell invasion (Han et al, 2000) (Figure 6A and B). These findings are in line with our previous work in which we demonstrated that a stable COX-2 downregulation in HT-29 cells, mediated by pH1-driven shCOX-2 expression, induces a significant impairment of malignant behaviour of HT-29 cells (Strillacci et al, 2006).
It is known that COX-2 has a key role in colon cancer progression and survival of colon cancer cells. Recently, we demonstrated that a COX-2/CA-IX (carbonic anhydrase IX) interplay controls CRC cell survival under hypoxic conditions (Sansone et al, 2009). Therefore, we aimed to demonstrate that COX-2 overexpression is also required for the survival of CRC cells after infection of invasive E. coli strains. As we have previously demonstrated (Strillacci et al, 2006), COX-2 stable silencing mediated by retroviral transduction did not affect proliferation and survival of HT-29 cells. In fact, we did not record any difference in the proliferation rate between HT-29pS(−) (negative control) and HT-29pS(shCOX−2) (in which COX-2 is stably downregulated). However, after a prolonged infection with invasive InvColi-pS− (MOI 1:100, 6 h incubation, day 0), we observed a significant difference in cell proliferation and cell viability between HT-29pS(−) and HT-29pS(shCOX−2) cells (Figure 7A and B). At MOI 1:100, bacterial infection rapidly induced COX-2 overexpression in HT-29pS(−) cells (days 1–4), most probably due to the higher presence of LPS (Hla and Neilson, 1992), but we did not observe this phenomenon in HT-29pS(shCOX−2) cells (Figure 7C). The lack of high COX-2 protein levels in infected HT-29pS(shCOX−2) cells led to a significant reduction in cell proliferation and viability. To further confirm the important role of the COX-2 protein in CRC cell survival, we performed InvColi-pS infection on HCT-116 cells, a CRC cell line not expressing the COX-2 protein. As expected, COX-2 protein and mRNA levels were not detectable in HCT-116 cells after 6 h infection with InvColi-pS strains at MOI 1:100 (data not shown). Importantly, the absence of COX-2 overexpression in infected HCT-116 cells led to a dramatic decrease in cell proliferation and viability (Figure 8A and B), as for HT-29pS(shCOX−2) cells. Moreover, infected HCT-116 cells showed a reduced ability to invade Matrigel-coated filters (Figure 8C).
We evaluated the efficacy of COX-2 silencing ex vivo using InvColi-based RNAi on fresh colon tissue samples. To this purpose, samples were collected from patients affected by acute ulcerative colitis, supposed to be characterised by COX-2 protein expression. Levels of COX-2 protein, COX-2 mRNA and siCOX-2 were analysed 48 h after infection of biopsies with InvColi-pS strains (MOI 1:1000, 6 h incubation). As shown in Figure 9A, negative controls (untreated sample and sample infected with InvColi-pS−) were characterised by COX-2 expression, as expected. A significant COX-2 protein/mRNA reduction and siCOX-2 expression were recorded in samples infected with InvColi-pSH1, InvColi-pSCOX2 and InvColi-pSTBE, compared with negative controls. Very importantly, InvColi-pSTBE infection had the strongest effect, further confirming the in vitro data (see above). We also evaluated the effect of COX-2 silencing in colon tissues by analysing the levels of PGE2, cytokines, chemokines and growth factors present in the conditioned media 48 h after infection. For this analysis, only tissue samples infected with InvColi-pS− (negative control) and InvColi-pSTBE (which showed the most effective COX-2 silencing) were taken into consideration and all data collected are shown in Figure 9B and C. As expected, COX-2 protein silencing mediated by InvColi-pSTBE led to a strong decrease in PGE2 secretion. Moreover, in media derived from InvColi-pSTBE-infected cells, we found a significant decrease in IL-1α, IL-1β, IL-6, IL-8, IL-12(p70), IL-17, PDGF-bb, bFGF, VEGF, IP-10, MCP-1 and MIP-1β, whereas we observed a marked increase in IL-1ra, IL-2, IL-15, TNFα and Eotaxin. Levels of IL-4, IL-5 and IL-10 were not detectable. Interestingly, COX-2 silencing led to a strong decrease in the secretion of pro-inflammatory cytokines such as IL-1α/β (Liu et al, 2003; Matsuo et al, 2009), IL-6 (Becker et al, 2005) or IL-8 (Brew et al, 2000), and that of pro-angiogenic growth factors such as PDGF-bb (Hsu et al, 1995), bFGF (Galzie et al, 1997) and VEGF (Takahashi et al, 1995). Furthermore, there was an increased secretion of some anti-inflammatory cytokines, such as IL-1ra (Konishi et al, 2005), and of cytokines with anti-tumour effect, such as IL-2 (Caporale et al, 2007) and IL-15 (Zhang et al, 2009). Similarly, TNFα increased secretion might exert an anti-tumour effect on colon cells, even if its role in CRC is still controversial (Koshiji et al, 1998; Popivanova et al, 2008). Thus, by a global analysis of ex vivo data, it results clear that InvColi-mediated RNAi induced COX-2 silencing and exerted an anti-inflammatory and anti-tumour effect on colon cells.
Over the last decades, a large body of experimental evidence has ascribed to the COX-2 enzyme an important role in colorectal tumourigenesis. Cyclooxygenase-2 is overexpressed in colon tumour tissues (Eberhart et al, 1994; Sano et al, 1995) and contributes to CRC progression and malignancy through mechanisms that act on cell proliferation/invasion (Yamauchi et al, 2002; Strillacci et al, 2006), apoptosis inhibition (Tsujii and DuBois, 1995) and tumour angiogenesis (Spisni and Tomasi, 1997; Iñiguez et al, 2003). It has been demonstrated that the chronic use of NSAIDs, inhibitors of COX activity, reduces CRC incidence in treated patients (Phillips et al, 2002; Thun et al, 2002; Higuchi et al, 2003; Sandler et al, 2003). Among these, ‘coxibs' have been developed and marketed for the selective block of COX-2 activity. Celecoxib, rofecoxib, lumiracoxib and etoricoxib have been employed in many clinical trials to test their safety associated with the chronic use, but data collected are debated. The high incidence of cardiovascular adverse events is associated with the chronic use of coxibs (Bresalier et al, 2005; Solomon et al, 2005) and it seems clear that other pharmacological strategies, based on COX-2 inhibition, are required for the prevention and/or treatment of CRC.
Cyclooxygenase can be efficiently and selectively inhibited by RNAi techniques, either in a transient or a long-lasting manner (Strillacci et al, 2006). RNAi has become the first choice for gene silencing in vitro despite many disadvantages of RNAi approaches in vivo. RNAi-based silencing molecules can be delivered in vivo by intravenous injections or expressed by the use of viral-based systems. However, poor pharmacodynamics and/or heavy side effects reduce their use and effectiveness in vivo.
Hereby, we provide data supporting an alternative approach to target CRC cells and induce a highly selective COX-2 silencing, mediated by RNAi, both in vitro and ex vivo. In particular, we engineered invasive E. coli strains (InvColi) carrying siCOX-2 (siRNA sequences targeting COX-2 mRNA)-expressing vectors (pSUPER.retro, pS). These bacteria were able to infect/invade CRC cells and release their DNA contents, leading to a strong COX-2 silencing.
First, we modified the pS vector to gain a tumour-specific shCOX-2 expression. The basic pS vector allows a constitutive expression of shCOX-2 (siCOX-2 precursor) in almost every human cell line as shCOX-2 transcription is driven by the H1 promoter for RNA pol III (pSH1). Thus, we modified this expression cassette by substituting the H1 promoter with the human Cox-2 promoter (in pSCOX−2) or with a promoter sequence containing TBEs (in pSTBE), which represent the downstream target sequences on human genomic DNA of the Wnt/β-catenin-activated pathway. It is well known that Cox-2 promoter activity is highly stimulated in CRC cells. Many cellular stimuli contribute to activate this phenomenon that leads to COX-2 overexpression (Yamamoto et al, 1995; Dixon et al, 2001; Duque et al, 2005; Wu et al, 2005; Kaidi et al, 2006; Strillacci et al, 2009). The Wnt/β-catenin pathway is highly activated in CRC cells and such an activation is caused by cellular stimuli or by mutation of proteins involved in the pathway, such as APC or β-catenin itself (Morin et al, 1997; Brabletz et al, 2001, 2005; Castellone et al, 2005). By the use of pSCOX−2 and pSTBE vectors, we demonstrated that siCOX-2 can be expressed in a more effective and selective manner in CRC cells. Under Cox-2 or a TBE-based promoter control, siCOX-2 expression in CRC cell lines (HT-29 and HCA-7) was higher, if compared with H1-driven expression. On the contrary, siCOX-2 resulted in very low expression in normal colon epithelial cells (NCM-460) or in other human tumour cell lines (such as HeLa and HEK-293).
Second, we demonstrated that shCOX-2-expressing vectors (pSH1, pSCOX−2 and pSTBE) can be efficiently delivered into HT-29 and HCA-7 CRC cell lines after infection with InvColi strains (MOI 1:1000), thus promoting a strong COX-2 downregulation (both at mRNA and protein levels) mediated by RNAi and a prolonged reduction in PGE2 levels. Most likely, this phenomenon led to the significant reduction in cell proliferation, viability and invasiveness observed in infected CRC cells. Very interestingly, shCOX-2 expression driven by the TBE promoter induced the highest COX-2 silencing, which resulted in a strong impairment of the tumour-associated phenotype. It seems clear that, by using the pSTBE vector, it is possible to gain both efficacy and specificity for COX-2 silencing in CRC cells.
We used our model to further demonstrate the pivotal role of COX-2 overexpression in CRC cell survival. By infecting HT-29 cells stably silenced for COX-2 (HT-29pS(shCOX−2), previously developed in our laboratory) with InvColi-pS− at a higher MOI value (1:100), we observed a significant reduction in cell proliferation and survival, with respect to the negative control (HT-29pS(−) cells). As it is well known that bacterial LPS induces COX-2 expression in human cells and, as we show herein, InvColi-pS− infection at an MOI 1:100 induces COX-2 overexpression in CRC cells, our hypothesis is that the survival of CRC cells after bacterial infection could be strictly dependent on COX-2 induction. This observation was further confirmed in HCT-116 cells, a CRC cell line unable to express COX-2. In fact, the lack of COX-2 protein induction after InvColi-pS strain infection led to a significant impairment of cell proliferation, viability and invasiveness of HCT-116 cells. We did not record differences between the four InvColi-pS strains used for HCT-116 infection. InvColi-pS− infection had the same effect of InvColi-pSH1, InvColi-pSCOX2 and InvColi-pSTBE infection. Thus, as for HT-29pS(shCOX−2), the biological effect on HCT-116 cells was dependent on InvColi-pS infection per se, rather than on siCOX-2 expression. On the other hand, the global effect of InvColi-pS infection on CRC cell lines expressing COX-2 (HCA-7 and HT-29) is the result of COX-2 silencing mediated by RNAi, PGE2 levels reduction and cellular stress induced by bacteria infection.
Finally, in the light of a possible in vivo application, we tested ex vivo the efficacy of selective COX-2 silencing mediated by InvColi-based RNAi. Colon tissue samples, derived from patients affected by acute ulcerative colitis and expressing COX-2 protein, were infected with InvColi-pS strains and this resulted in a strong COX-2 inhibition at both mRNA and protein levels, especially after infection with InvColi-pSTBE. Cyclooxygenase-2 silencing was associated with a significant reduction in PGE2 and pro-inflammatory/pro-angiogenic factors (cytokines, growth factors) released by colon InvColi-pSTBE-infected cells. Moreover, we observed an increased production of factors with anti-inflammatory and anti-tumour effects.
In conclusion, we developed an RNAi-based strategy to efficiently and specifically silence the COX-2 protein in CRC cells, in vitro and ex vivo. Cyclooxygenase-2 downregulation, depending on InvColi-pS infection, induced a strong impairment of both proliferative and invasive behaviour of CRC cells in vitro and a significant anti-inflammatory and anti-tumour effect ex vivo. Taken together, our data demonstrate the feasibility of an RNAi-based/InvColi-driven approach for COX-2 silencing aimed at the prevention of CRC or the treatment of other inflammatory bowel diseases characterised by COX-2 overexpression. Using engineered E. coli strains or other non-pathogenic bacteria, siCOX-2 silencing could be locally delivered and expressed in colorectal tissues, thus promoting a blockade of COX-2 activity, supposedly deprived of systemic side effects.
Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
This work was supported by grants from MIUR (FIRB 2003 RBNE03FMCJ to VT and PRIN 2008MT34AP to ES). We also thank Dr Catherine Grillot-Courvalin (Unité des Agents Antibactériens, Institut Pasteur, Paris) for providing us pGB2-Ω-inv-hly plasmid and Dr Hans Clevers (University Hospital, Utrecht, The Netherlands) for providing us TOPFLASH plasmid.
|Becker C,Fantini MC,Wirtz S,Nikolaev A,Lehr HA,Galle PR,Rose-John S,Neurath MF. Year: 2005IL-6 signaling promotes tumor growth in colorectal cancerCell Cycle421722015655344|
|Brabletz T,Hlubek F,Spaderna S,Schmalhofer O,Hiendlmeyer E,Jung A,Kirchner T. Year: 2005Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-cateninCells Tissues Organs179566515942193|
|Brabletz T,Jung A,Reu S,Porzner M,Hlubek F,Kunz-Schughart LA,Knuechel R,Kirchner T. Year: 2001Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environmentProc Natl Acad Sci USA981035610361|
|Bresalier RS,Sandler RS,Quan H,Bolognese JA,Oxenius B,Horgan K,Lines C,Riddell R,Morton D,Lanas A,Konstam MA,Baron JA,Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial InvestigatorsYear: 2005Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med3521092110215713943|
|Brew R,Erikson JS,West DC,Kinsella AR,Slavin J,Christmas SE. Year: 2000Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitroCytokine12788510623446|
|Brummelkamp TR,Bernards R,Agami R. Year: 2002Stable suppression of tumorigenicity by virus-mediated RNA interferenceCancer Cell224324712242156|
|Caporale A,Brescia A,Galati G,Castelli M,Saputo S,Terrenato I,Cucina A,Liverani A,Gasparrini M,Ciardi A,Scarpini M,Cosenza UM. Year: 2007Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine modelAnticancer Res2798598917465231|
|Castagliuolo I,Beggiao E,Brun P,Barzon L,Goussard S,Manganelli R,Grillot-Courvalin C,Palù G. Year: 2005Engineered E. coli delivers therapeutic genes to the colonic mucosaGene Ther121070107815815705|
|Castellone MD,Teramoto H,Williams BO,Druey KM,Gutkind JS. Year: 2005Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axisScience3101504151016293724|
|Chen C,Ridzon DA,Broomer AJ,Zhou Z,Lee DH,Nguyen JT,Barbisin M,Xu NL,Mahuvakar VR,Andersen MR,Lao KQ,Livak KJ,Guegler KJ. Year: 2005Real-time quantification of microRNAs by stem-loop RT-PCRNucleic Acids Res33e17916314309|
|Crofford LJ,Wilder RL,Ristimäki AP,Sano H,Remmers EF,Epps HR,Hla T. Year: 1994Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroidsJ Clin Invest93109511018132748|
|Dixon DA,Tolley ND,King PH,Nabors LB,McIntyre TM,Zimmerman GA,Prescott SM. Year: 2001Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cellsJ Clin Invest1081657166511733561|
|DuBois RN,Radhika A,Reddy BS,Entingh AJ. Year: 1996Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumorsGastroenterology110125912628613017|
|Duque J,Fresno M,Iñiguez MA. Year: 2005Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2J Biol Chem2808686869315632146|
|Eberhart CE,Coffey RJ,Radhika A,Giardiello FM,Ferrenbach S,DuBois RN. Year: 1994Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomasGastroenterology107118311887926468|
|Ferlay J,Autier P,Boniol M,Heanue M,Colombet M,Boyle P. Year: 2007Estimates of the cancer incidence and mortality in Europe in 2006Ann Oncol1858159217287242|
|Galzie Z,Fernig DG,Smith JA,Poston GJ,Kinsella AR. Year: 1997Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factorInt J Cancer713903959139874|
|Griffoni C,Spisni E,Strillacci A,Toni M,Bachschmid MM,Tomasi V. Year: 2007Selective inhibition of prostacyclin synthase activity by rofecoxibJ Cell Mol Med1132733817488481|
|Grillot-Courvalin C,Goussard S,Huetz F,Ojcius DM,Courvalin P. Year: 1998Functional gene transfer from intracellular bacteria to mammalian cellsNat Biotechnol168628669743121|
|Han SY,Lee MS,Kim HR,Baek SH,Ahn DH,Chae HS,Erickson RH,Sleisenger MH,Kim YS. Year: 2000Phorbol 12-myristate 13-acetate induces alteration in mucin gene expression and biological properties of colon cancer cellsInt J Oncol1748749410938388|
|Higuchi T,Iwama T,Yoshinaga K,Toyooka M,Taketo MM,Sugihara K. Year: 2003A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patientsClin Cancer Res94756476014581346|
|Hla T,Neilson K. Year: 1992Human cyclooxygenase-2 cDNAProc Natl Acad Sci USA8973847388|
|Hsu S,Huang F,Friedman E. Year: 1995Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effectJ Cell Physiol1652392457593201|
|Iñiguez MA,Rodriguez A,Volpert OV,Fresno M,Redondo JM. Year: 2003Cyclooxygenase-2: a therapeutic target in angiogenesisTrends Mol Med9737812615041|
|Kaidi A,Qualtrough D,Williams AC,Paraskeva C. Year: 2006Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxiaCancer Res666683669116818642|
|Konishi N,Miki C,Yoshida T,Tanaka K,Toiyama Y,Kusunoki M. Year: 2005Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinomaOncology6813814516006751|
|Koshiji M,Adachi Y,Sogo S,Taketani S,Oyaizu N,Than S,Inaba M,Phawa S,Hioki K,Ikehara S. Year: 1998Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expressionClin Exp Immunol1112112189472684|
|Lewis DL,Hagstrom JE,Loomis AG,Wolff JA,Herweijer H. Year: 2002Efficient delivery of siRNA for inhibition of gene expression in postnatal miceNat Genet3210710812145662|
|Liu W,Reinmuth N,Stoeltzing O,Parikh AA,Tellez C,Williams S,Jung YD,Fan F,Takeda A,Akagi M,Bar-Eli M,Gallick GE,Ellis LM. Year: 2003Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathwaysCancer Res633632363612839952|
|Matsuo Y,Sawai H,Ma J,Xu D,Ochi N,Yasuda A,Takahashi H,Funahashi H,Takeyama H. Year: 2009IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasisJ Surg Oncol9936136719204921|
|Morin PJ,Sparks AB,Korinek V,Barker N,Clevers H,Vogelstein B,Kinzler KW. Year: 1997Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APCScience275178717909065402|
|Moyer MP,Manzano LA,Merriman RL,Stauffer JS,Tanzer LR. Year: 1996NCM460, anormal human colon mucosal epithelial cell lineIn Vitro Cell Dev Biol Anim323153178842743|
|Oshima M,Dinchuk JE,Kargman SL,Oshima H,Hancock B,Kwong E,Trzaskos JM,Evans JF,Taketo MM. Year: 1996Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)Cell878038098945508|
|Phillips RK,Wallace MH,Lynch PM,Hawk E,Gordon GB,Saunders BP,Wakabayashi N,Shen Y,Zimmerman S,Godio L,Rodrigues-Bigas M,Su LK,Sherman J,Kelloff G,Levin B,Steinbach G,FAP Study GroupYear: 2002A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposisGut5085786012010890|
|Popivanova BK,Kitamura K,Wu Y,Kondo T,Kagaya T,Kaneko S,Oshima M,Fujii C,Mukaida N. Year: 2008Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitisJ Clin Invest11856057018219394|
|Sandler RS,Halabi S,Baron JA,Budinger S,Paskett E,Keresztes R,Petrelli N,Pipas JM,Karp DD,Loprinzi CL,Steinbach G,Schilsky R. Year: 2003A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancerN Engl J Med34888389012621132|
|Sano H,Kawahito Y,Wilder RL,Hashiramoto A,Mukai S,Asai K,Kimura S,Kato H,Kondo M,Hla T. Year: 1995Expression of cyclooxygenase-1 and -2 in human colorectal cancerCancer Res55378537897641194|
|Sansone P,Piazzi G,Paterini P,Strillacci A,Ceccarelli C,Minni F,Biasco G,Chieco P,Bonafè M. Year: 2009Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cellsJ Cell Mol Med133876388719017360|
|Sledz CA,Holko M,de Veer MJ,Silverman RH,Williams BRG. Year: 2003Activation of the interferon system by short-interfering RNAsNature Cell Biol583483912942087|
|Solomon SD,McMurray JJ,Pfeffer MA,Wittes J,Fowler R,Finn P,Anderson WF,Zauber A,Hawk E,Bertagnolli M,Adenoma Prevention with Celecoxib (APC) Study InvestigatorsYear: 2005Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionN Engl J Med3521071108015713944|
|Spisni E,Tomasi V. Year: 1997Involvement of prostanoid in angiogenesisTumour AngiogenesisBicknell R, Lewis CE, Ferrara N (Eds). Oxford University Press: Oxford, UK291300|
|Strillacci A,Griffoni C,Sansone P,Paterini P,Piazzi G,Lazzarini G,Spisni E,Pantaleo MA,Biasco G,Tomasi V. Year: 2009MiR-101 is involved in cyclooxygenase-2 overexpression in human colon cancer cellsExp Cell Res3151439144719133256|
|Strillacci A,Griffoni C,Spisni E,Manara MC,Tomasi V. Year: 2006RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumor cellsBr J Cancer941300131016622456|
|Strillacci A,Griffoni C,Valerii MC,Lazzarini G,Tomasi V,Spisni E. Year: 2010RNAi-based strategies for cyclooxygenase-2 (COX-2) inhibition in cancer. RNAi-based strategies for cyclooxygenase-2 (COX-2) inhibition in cancerJ Biomed Biotechnol201082804520625420|
|Takahashi Y,Kitadai Y,Bucana CD,Cleary KR,Ellis LM. Year: 1995Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancerCancer Res55396439687664263|
|Thun MJ,Henley SJ,Patrono C. Year: 2002Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issuesJ Natl Cancer Inst9425226611854387|
|Tsujii M,DuBois RN. Year: 1995Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell834935018521479|
|Williams CS,Luongo C,Radhika A,Zhang T,Lamps LW,Nanney LB,Beauchamp RD,DuBois RN. Year: 1996Elevated cyclooxygenase-2 levels in Min mouse adenomasGastroenterology111113411408831610|
|Wu KK,Liou JY,Cieslik K. Year: 2005Transcriptional control of COX-2 via C/EBPbetaArterioscler Thromb Vasc Biol2567968515681294|
|Xiang S,Fruehauf J,Li CJ. Year: 2006Short hairpin RNA–expressing bacteria elicit RNA interference in mammalsNat Biotechnol2469770216699500|
|Yamamoto K,Arakawa T,Ueda N,Yamamoto S. Year: 1995Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cellsJ Biol Chem27031315313208537402|
|Yamauchi T,Watanabe M,Kubota T,Hasegawa H,Ishii Y,Endo T,Kabeshima Y,Yorozuya K,Yamamoto K,Mukai M,Kitajima M. Year: 2002Cyclooxygenase-2 expression as a new marker for patients with colorectal cancerDis Colon Rectum459810311786771|
|Zhang M,Yao Z,Dubois S,Ju W,Müller JR,Waldmann TA. Year: 2009Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancerProc Natl Acad Sci USA10675137518|
Keywords: COX-2, CRC, RNAi, E. coli.
Previous Document: SV40 associated miRNAs are not detectable in mesotheliomas.
Next Document: Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patient...